Page last updated: 2024-09-05

erlotinib hydrochloride and Cancer, Embryonal

erlotinib hydrochloride has been researched along with Cancer, Embryonal in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amatruda, JF; Ateek, C; Budhipramono, A; Chen, KS; Frazier, AL; Fustino, NJ; Kapur, P; Laetsch, TW; Looijenga, LHJ; Lum, L; Rakheja, D; Shukla, AA; Stroup, EK; Stuart, SH; Yamaguchi, K	1
Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD	1
Bee, T; Black, CC; Dmitrovsky, E; Ewings, KE; Freemantle, SJ; Hattab, EM; Kelley, MR; Krizan, KA; Memoli, VA; Spinella, MJ; Vaseva, AV	1

Trials

1 trial(s) available for erlotinib hydrochloride and Cancer, Embryonal

Article	Year
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide	2008

Article

Year

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide

2008

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Cancer, Embryonal

Article	Year
EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors. Molecular cancer therapeutics, 2018, Volume: 17, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin Receptor Common gamma Subunit; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Sirolimus; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2018
Repression of cyclin D1 as a target for germ cell tumors. International journal of oncology, 2007, Volume: 30, Issue:2 Topics: Antineoplastic Agents; Cell Differentiation; Cyclin D1; DNA Fragmentation; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Germ Cell and Embryonal; Quinazolines; Receptors, Retinoic Acid; RNA, Heterogeneous Nuclear; RNA, Small Interfering; Time Factors; Tretinoin	2007

Article

Year

EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Molecular cancer therapeutics, 2018, Volume: 17, Issue:5

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin Receptor Common gamma Subunit; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Sirolimus; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays

2018

Repression of cyclin D1 as a target for germ cell tumors.

International journal of oncology, 2007, Volume: 30, Issue:2

Topics: Antineoplastic Agents; Cell Differentiation; Cyclin D1; DNA Fragmentation; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Germ Cell and Embryonal; Quinazolines; Receptors, Retinoic Acid; RNA, Heterogeneous Nuclear; RNA, Small Interfering; Time Factors; Tretinoin

2007